Related Experiment Video
Updated: Jan 23, 2026
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review
Sina Neshat1, Hazhir Moradi2, Matin Bidares3
1Department of Biostatistics and Epidemiology, University of California San Francisco, San Francisco, USA.
Abstract:
In heart failure (HF), atherogenic dyslipidemia and lipotoxicity contribute to adverse remodeling. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve HF outcomes, yet their lipid effects remain debated. This review aims to synthesize quantitative changes in lipid parameters and plausible mechanisms by which SGLT2i modulate lipoproteins in HF. Across trials and HF-focused cohorts, SGLT2i are associated with small increases in low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) and small decreases in triglycerides. Beyond concentrations, emerging data suggest qualitative remodeling - a shift toward less atherogenic LDL phenotypes (small-dense LDL (sd-LDL)↓) and increases in HDL2 - although evidence is limited and heterogeneous. Mechanistically, enhanced adipose lipolysis and hepatic β-oxidation/ketogenesis may raise ketone availability for the myocardium ("thrifty substrate"), while hepatic cholesterol pool-driven LDL receptor (LDLR) downregulation could explain modest LDL-C increases. These lipid shifts coexist with consistent reductions in HF events, independent of diabetes, implying benefits not captured by traditional lipid metrics alone. In HF, SGLT2i likely exert modest quantitative lipid changes but potentially meaningful qualitative lipoprotein remodeling alongside improved metabolic flexibility. Clinically, apolipoprotein B (ApoB)-targeted therapy (e.g., statins ± ezetimibe) remains essential when LDL-C/ApoB are above goal, with SGLT2i used for cardiorenal benefit. HF-specific trials powered for ApoB, sd-LDL, low-density lipoprotein particle number (LDL-P), HDL function, and lipidomics are lacking. In conclusion, SGLT2i produce small, mixed lipid changes in HF, but mechanistic and particle-level effects may align with improved outcomes; definitive HF-centric lipid studies are a priority.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show modest lipid changes in heart failure (HF), potentially improving lipoprotein quality and metabolic flexibility, contributing to better HF outcomes.
Area of Science:
- Cardiology
- Metabolic Diseases
- Pharmacology
Background:
- Atherogenic dyslipidemia and lipotoxicity are key drivers of adverse cardiac remodeling in heart failure (HF).
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated significant benefits in HF outcomes, but their precise effects on lipid profiles are not fully understood.
Purpose of the Study:
- To review and synthesize quantitative and qualitative changes in lipid parameters associated with SGLT2i use in HF patients.
- To explore the potential mechanisms by which SGLT2i influence lipoprotein metabolism in the context of HF.
Main Methods:
- Systematic review of clinical trials and HF-specific cohorts examining lipid profiles in patients treated with SGLT2i.
- Analysis of emerging data on qualitative lipoprotein remodeling, including LDL particle size and HDL subclasses.
- Exploration of proposed mechanistic pathways involving adipose tissue lipolysis, hepatic metabolism, and ketone body utilization.
Main Results:
- SGLT2i are associated with minor increases in LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C), and slight decreases in triglycerides.
- Emerging evidence suggests SGLT2i may promote a shift towards less atherogenic LDL phenotypes (e.g., decreased small-dense LDL) and increased HDL2 levels.
- Proposed mechanisms include enhanced lipolysis, increased hepatic beta-oxidation and ketogenesis, potentially providing a "thrifty substrate" for the myocardium.
Conclusions:
- SGLT2i induce modest quantitative lipid alterations but may confer significant qualitative lipoprotein remodeling in HF, contributing to improved metabolic flexibility and HF outcomes.
- These lipid effects appear independent of diabetes status and suggest benefits beyond traditional lipid-lowering.
- Further HF-specific trials are needed to definitively assess ApoB, sd-LDL, LDL-P, HDL function, and lipidomics to fully elucidate SGLT2i's role in HF lipid management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:22Heart Failure VI: Adjunct Therapies
01:22Heart Failure Drugs: Diuretics